Price (GBX)
101.00 4.12%
STXORD 1.5P
Track
Open / Last close
- / 101.00
High / Low
101.00 / 100.00
Bid / Offer
97.00 / 105.00
Turnover
£990.00
Special Condition: -
Trading Status: Post-Close
As at 05.06.20 16:43:37 - All data delayed at least 15 minutes

Shield Therapeutics PLC instruments

Select instrument to view
Equity (1)
Code Instrument name Price Change Type Documentation
STXORD 1.5P101.00
GBX
4.12%Equity-

Price information

What's this?
Open price
-
Previous close price / date
101.00 / 05 June 2020
Volume
131,543
Turnover
£990.00
52 week range
54.00 / 196.00
YTD return
-44.04
1 year return
-16.18

Instrument information

What's this?
Instrument market cap (£m)
113.67
Earnings per share
-0.02
Dividend (yield)
- %
Issue date
26 February 2016
ISIN
GB00BYV81293
SEDOL
BYV8129
Market identifier code (MIC)
AIMX
Country of share register
GB
Market segment
ASQ1
Trading service
SETSqx
Date Time Price CurrencyVolume Trade ValueTrade type Trade flag MIC
05.06.20 16:37:42 101.00 GBX 12,592 12,717.92 Off-Book - SINT
05.06.20 16:22:34 104.04 GBX 720 749.09 Off-Book - AIMX
05.06.20 16:04:34 100.00 GBX 10,000 10,000.00 Off-Book PRIC AIMX
05.06.20 14:50:00 105.00 GBX 3,108 3,263.40 Off-Book - AIMX
05.06.20 12:53:35 99.10 GBX 2,000 1,982.00 Off-Book - AIMX

Equity Research

from Shield Therapeutics PLC
The Monthly June 2020

Much has been written about the effects of the virus on the world and on the stock market. Here is one analyst’s take on some of the likely impacts on the way we should look at companies. This article was originally produced as a blog, “10 Changes Post Virus”, which was published a few weeks ago.

View report
Shield Therapeutics - All eyes on a US partnering deal

Shield Therapeutics (STX) has reported FY19 results; total revenue of £0.7m reflects royalties on Feraccru sales from European partner Norgine. 2019 achievements include FDA approval of STX’s key asset for the treatment of iron deficiency in patients with any underlying cause – the broadest possible label – in the critical US market. Momentum has continued into 2020 with an out-licensing deal with China-based Beijing Aosaikang Pharmaceutical (ASK Pharm) that covers China, Hong Kong, Macau and Taiwan. The next key inflection point is a US partnering deal, and discussions are ongoing with the aim of closing a transaction at the earliest opportunity in 2020. We expect Accrufer launch later this year once a partner has been found. STX reported a cash balance of £10.4m at 30 April 2020 implying a cash runway to Q121. We value Shield at £381.7m.

View report
Morning Note – 21 May 2020

Belvoir Group (BLV): Corp April significantly stronger than anticipated | Bigblu Broadband (BBB): Corp Reassuring update with strong organic customer growth | ClearStar (CLSU): Corp New COVID-19 testing service | KRM22 (KRM): Corp Finals to December 2019 | Oncimmune Holdings (ONC): Corp EarlyCDT Lung partnership | Shield Therapeutics (STX): Corp FY 2019 results | Universe Group (UNG): Corp FY19 on track, with a good start to FY20

View report
FY 2019 results

Shield reported FY 2019 results that showed sustained momentum from Norgine’s promotional activity of Feraccru in England and Germany, with in-market pack volumes c.70% higher than in 2018. Revenues of £0.7m compared with £11.9m in 2018, which included £11m of milestones. This resulted in an adjusted net loss of £6.3m (vs +£1.1m). Net cash at 30 June was £4.1m, providing a cash runway into Q1 2021, which excludes potential significant up-front payment

View report
SP Angel Healthcare Conditions

Beximco Pharma (BXP.L*): Launch of generic version of remdesivir | Feedback plc (FDBK.L*): Contract renewal at the Royal Papworth Hospital NHS Foundation Trust | Shield Therapeutics (STX.L): Preliminary results for 2019

View report

Contacts

from Shield Therapeutics PLC
CFO
Tim Watts
atShield Therapeutics PLC
twatts@shieldtx.com
Investor Relations
Karen Chandler-Smith
atShield Therapeutics PLC
kchandler-smith@shieldtherapeutics.com
Issuer presentations live and on demand
Watch on Spark Live